Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup led by a chief executive hot off of his third acquisition deal.
Atlas, Bain, and RTW Investments announced Tuesday that they have co-led a $400 million Series A financing for a new Boston-area startup company called Kailera Therapeutics. The investors have also brought in a familiar face: Ron Renaud, who recently oversaw the $8.7 billion acquisition of Cerevel Therapeutics, a spinout of Pfizer assets that Bain helped finance back in 2018.
Kailera’s series A round total is one of the largest in the biotech industry this year, and speaks to just how much attention weight loss medications have garnered from investors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in